Management of Bradycardia in Patients on Multiple Medications

Initial Assessment

• The American College of Cardiology recommends evaluating if the bradycardia is symptomatic (heart rate <50 beats/min with symptoms) or asymptomatic, checking for symptoms of poor perfusion: dizziness, lightheadedness, syncope, confusion, or hypotension 1
• Obtain a 12-lead ECG to determine if there is sinus bradycardia or more concerning second or third-degree heart block 1, 2
• Review the patient's medication list to identify drugs contributing to bradycardia, including other medications that may contribute (methotrexate, escitalopram) 3

Management Algorithm

• For symptomatic bradycardia, the American College of Cardiology suggests immediately discontinuing or reducing the dose of rate-limiting medications, particularly amlodipine, telmisartan, and indapamide, while monitoring for hemodynamic improvement 3, 2
• If symptoms persist, administer atropine 0.5 mg IV every 3-5 minutes up to a total of 3 mg for temporary improvement 1, 2
• For refractory cases with severe symptoms, consider transcutaneous pacing and cardiology consultation for possible transvenous pacing 2, 1

Medication-Specific Considerations

• In patients with bradycardia associated with symptoms or hemodynamic compromise due to calcium channel blocker effects, intravenous calcium is reasonable to increase heart rate and improve symptoms 3, 2
• If bradycardia persists despite medication adjustments, glucagon or high-dose insulin therapy may be considered for severe cases 3, 2

Monitoring Recommendations

• Implement continuous cardiac monitoring for patients with symptomatic bradycardia 1
• Perform regular vital sign checks (heart rate, blood pressure) for 24-48 hours after adjusting medications 1
• Target heart rate >50 BPM if asymptomatic, higher if symptomatic 1

Long-term Considerations

• If the patient continues to have symptomatic bradycardia despite medication adjustments, consider electrophysiology consultation for possible pacemaker implantation 4, 2
• Regular ECG monitoring should be performed during follow-up to assess heart rate and conduction intervals 4

Management of Symptomatic Bradycardia

Medication Management

• Sotalol can cause bradycardia, requiring permanent pacemaker implantation in some patients, and this adverse effect is well-documented, according to the American Heart Association 5, 6
• The American College of Cardiology recommends that patients with symptomatic bradycardia due to sotalol should have their dose reduced or discontinued, with monitoring of heart rate response over 3-5 days 5, 6, 7
• For patients with minimal structural heart disease, the American Heart Association suggests considering flecainide 100-300 mg/day or propafenone 450-900 mg/day as alternative antiarrhythmic agents 8
• For patients with structural heart disease or heart failure, the European Society of Cardiology recommends amiodarone as the preferred alternative, though it also can cause bradycardia 5, 6, 9, 10

Monitoring and Follow-up

• The American College of Cardiology recommends performing an ECG within 3-5 days of dose adjustment to assess QT interval and rhythm 6
• Weekly heart rate monitoring for the first month is recommended, using pulse checks, event recorder, or office ECG 6
• The American Heart Association suggests reassessing symptoms and vital signs after initial dose reduction, with follow-up office visits at 24-48 hours, 3-5 days, and weekly for 1 month 6